Vir Biotechnologyincis A Clinical Stage Immunology Company Based In San Franciscocaliforniafounded In January 2016The Company Focuses On Developing Innovative Treatments For Infectious Diseasesleveraging The Immune System To Address Critical Medical Needswith Significant Initial Funding From Arch Venture Partners And The Bill & Melinda Gates Foundationvir Biotechnology Aims To Improve Patient Outcomes Through Its Advanced Technologies The Company S Pipeline Includes Treatments For Chronic Hepatitis Delta And Bhivrespiratory Syncytial Virusinfluenzacovid 19And Oncologyvir Biotechnology Utilizes Two Main Technology Platformsthe Next Generation Antibody Platform For Rapid Development Of Antibody Candidates And The Pro Xtena C Protease Releasable Masking Technology For Applications In Infectious Diseases And Cancerthe Company Collaborates With Major Pharmaceutical Partnersincluding A Research Partnership With Gsk For Covid 19 Therapies Vir Biotechnology Has Been Recognized For Its Rapid Growthbeing Named The Fastest Growing Company In North America On The 2023 Deloitte Technology Fast 500The Company S Mission Is To Create A World Without Infectious Diseases By Delivering Transformative Medicines To Patients In Need
